California State Teachers Retirement System Purchases 104,338 Shares of Royalty Pharma plc (NASDAQ:RPRX)

California State Teachers Retirement System boosted its position in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 13.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 876,268 shares of the biopharmaceutical company's stock after buying an additional 104,338 shares during the quarter. California State Teachers Retirement System owned 0.15% of Royalty Pharma worth $22,354,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Nissay Asset Management Corp Japan ADV boosted its stake in Royalty Pharma by 0.7% during the fourth quarter. Nissay Asset Management Corp Japan ADV now owns 48,481 shares of the biopharmaceutical company's stock worth $1,238,000 after buying an additional 349 shares during the period. Keene & Associates Inc. boosted its stake in shares of Royalty Pharma by 1.9% during the fourth quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company's stock valued at $495,000 after purchasing an additional 370 shares during the period. National Bank of Canada FI boosted its stake in shares of Royalty Pharma by 21.8% during the fourth quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 371 shares during the period. Blue Trust Inc. boosted its stake in shares of Royalty Pharma by 31.3% during the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 376 shares during the period. Finally, Sherbrooke Park Advisers LLC boosted its stake in shares of Royalty Pharma by 1.1% during the fourth quarter. Sherbrooke Park Advisers LLC now owns 34,891 shares of the biopharmaceutical company's stock valued at $890,000 after purchasing an additional 380 shares during the period. 54.35% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RPRX has been the subject of a number of recent analyst reports. Citigroup reissued a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. Morgan Stanley initiated coverage on shares of Royalty Pharma in a research note on Friday, May 16th. They set an "overweight" rating and a $51.00 target price for the company. Finally, Wall Street Zen lowered shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research note on Tuesday, May 20th. Two research analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $42.50.

Royalty Pharma Stock Up 0.7%

NASDAQ:RPRX traded up $0.25 during mid-day trading on Monday, reaching $33.13. The company's stock had a trading volume of 2,035,243 shares, compared to its average volume of 4,781,515. The firm has a market capitalization of $18.62 billion, a PE ratio of 22.84, a price-to-earnings-growth ratio of 2.31 and a beta of 0.49. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64. The stock has a fifty day moving average of $32.31 and a 200-day moving average of $30.45. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $34.31.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts' consensus estimates of $0.99 by $0.07. The business had revenue of $839.00 million during the quarter, compared to the consensus estimate of $724.69 million. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Equities research analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a $0.22 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a yield of 2.66%. Royalty Pharma's dividend payout ratio is presently 47.57%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.